Tissue Regenix Group Plc (TRX)

London
0.440
0.000(0.00%)
  • Volume:
    16,326,994
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    0.440 - 0.440

TRX Overview

Prev. Close
0.44
Day's Range
0.44-0.44
Revenue
19.16M
Open
0.44
52 wk Range
0.33-0.77
EPS
0
Volume
16,326,994
Market Cap
30.52M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
10,467,566
P/E Ratio
-
Beta
2.43
1-Year Change
-31.78%
Shares Outstanding
7,016,964,699
Next Earnings Date
05 Sept 2022
What is your sentiment on Tissue Regenix?
or
Market is currently closed. Voting is open during market hours.

Tissue Regenix Group Plc News

Tissue Regenix Group Plc Company Profile

Tissue Regenix Group Plc Company Profile

Employees
79

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, Decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient’s own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure products; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks for ophthalmology and wound covering; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellStrong SellStrong Sell
Technical IndicatorsSellBuyBuyStrong SellStrong Sell
SummaryStrong SellNeutralNeutralStrong SellStrong Sell
  • Below is a comprehensive background research article on TRX
    0
    • https://www.reddit.com/user/Jessie1991a/comments/krab7q/jessies_first_write_up/
      0
      • This stock has a huge potential medium/long term
        0
        • https://metro.co.uk/2021/02/18/scientists-regrow-and-repair-liver-from-lab-grown-cells-in-world-first-14098497/
          0
          • will this keep going up? thoughts?
            0
            • Regenerative medicine is the future
              0
              • what are people thinking
                3
                • Moving well today. Let's hope we see 8p again in 2020.
                  1
                  • The rise will happen just need to be patience and hold stock.
                    1
                    • Holding
                      0
                  • Will it go that far today
                    0